HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated presented data from a Phase 1 clinical trial showing that KOS-1584/R1645, an epothilone under co-development with Roche, demonstrated promising antitumor activity and tolerability in patients with solid tumors. KOS-1584/R1645 showed activity in 32% of patients (13 of 41 evaluable) including activity in patients with non-small cell lung, ovarian, breast, prostate, head and neck and other cancers. Common toxicities were generally low-grade and manageable. Data from this ongoing trial were presented on Sunday, June 3, 2007, in a poster titled, "Phase 1 Trial of KOS-1584 (a Novel Epothilone) Using Two Weekly Dosing Schedules," by Howard Burris, M.D., Sarah Cannon Research Institute, Nashville, TN, at the 2007 Annual Meeting of the American Society of Clinical Oncology (ASCO).
"Epothilones are promising anticancer agents due to their taxane-like mechanism of action and demonstrated activity in taxane resistant tumors," said Dr. Burris. "Kosan's novel epothilone is of particular interest due to its level of antitumor activity in patients with highly refractory disease and manageable side effect profile. This promising compound warrants continued development."
"KOS-1584/R1645 is a highly potent compound with attractive
pharmaceutical properties, including a long half-life, large volume
of distribution, wide therapeutic index and ease of formulation
that has demonstrated encouraging activity in Phase 1 trials," said
Robert G. Johnson, Jr., M.D., Ph.D., Kosan's President and Chief
Executive Officer. "We believe that KOS-1584/R1645, based on our
novel epothilone D backbone, has the potential to be superior to
other epothilones currently in development and ultimately emerge as
a meaningful competitor in the taxane market. We look forward to
initiating a robust Phase 2 clinical program, with the support of
our partner Roch